SG Americas Securities LLC Has $173,000 Stake in Illumina, Inc. (NASDAQ:ILMN)

SG Americas Securities LLC lowered its holdings in Illumina, Inc. (NASDAQ:ILMN) by 18.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,292 shares of the life sciences company’s stock after selling 290 shares during the period. SG Americas Securities LLC’s holdings in Illumina were worth $173,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Zacks Investment Management acquired a new position in Illumina during the 3rd quarter valued at about $2,924,000. Freemont Management S.A. bought a new stake in shares of Illumina in the 3rd quarter valued at $1,565,000. Assenagon Asset Management S.A. lifted its holdings in shares of Illumina by 5.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 42,748 shares of the life sciences company’s stock valued at $5,712,000 after purchasing an additional 2,338 shares in the last quarter. CCLA Investment Management boosted its holdings in shares of Illumina by 20.5% in the fourth quarter. CCLA Investment Management now owns 535,050 shares of the life sciences company’s stock valued at $71,493,000 after buying an additional 91,122 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Illumina by 65.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 32,806 shares of the life sciences company’s stock worth $4,278,000 after purchasing an additional 12,986 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ILMN shares. Canaccord Genuity Group cut their price objective on shares of Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research report on Friday. Stephens upped their price objective on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Guggenheim cut their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday. Morgan Stanley lowered their price target on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, Robert W. Baird boosted their price objective on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Nine research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $161.40.

Illumina Price Performance

ILMN stock opened at $111.06 on Monday. The company has a 50 day simple moving average of $136.70 and a 200 day simple moving average of $135.43. The stock has a market cap of $17.61 billion, a price-to-earnings ratio of -14.46 and a beta of 1.10. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a 1 year low of $100.08 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. Research analysts anticipate that Illumina, Inc. will post 4.42 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.